Predicted protein targets (top 10)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | THRB | P10828 | 1/20 | 0.37 |
| ▸ | HTT | P42858 | 1/20 | 0.37 |
| ▸ | MAPT | P10636 | 1/20 | 0.37 |
| ▸ | TSHR | P16473 | 2/20 | 0.36 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.36 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | CYP4F2 | P78329 | 1/20 | 0.35 |
| ▸ | CYP4A11 | Q02928 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL21106744 | 0.87 | APLNR (0.30) | — | |
| SCHEMBL12967160 | 0.86 | ALDH1A1 (0.32) | TSHRALDH1A1 | |
| SCHEMBL20057022 | 0.86 | EPHX2 (0.31) | — | |
| SCHEMBL29334924 | 0.84 | CYP4F2 (0.47) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL1401683 | 0.83 | MEN1 (0.44) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL13799308 | 0.83 | MEN1 (0.44) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL1401413 | 0.83 | MEN1 (0.44) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL30244596 | 0.83 | MEN1 (0.44) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL4508237 | 0.83 | MEN1 (0.44) | MEN1KMT2ATHRBHTTMAPT | |
| SCHEMBL17822966 | 0.83 | MEN1 (0.44) | MEN1KMT2ATHRBHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2021-07-22 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210220475-A1 | EGFR PROTEOLYSIS TARGETING CHIMERIC MOLECULES AND ASSOCIATED METHODS OF USE | TBK1, EGFR, CBL | MEN1 3927/4885KMT2A 2593/4885THRB 1970/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.